CO6241126A2 - Nuevos derivados de 4,8-difenil-poliazanaftaleno - Google Patents
Nuevos derivados de 4,8-difenil-poliazanaftalenoInfo
- Publication number
- CO6241126A2 CO6241126A2 CO09120187A CO09120187A CO6241126A2 CO 6241126 A2 CO6241126 A2 CO 6241126A2 CO 09120187 A CO09120187 A CO 09120187A CO 09120187 A CO09120187 A CO 09120187A CO 6241126 A2 CO6241126 A2 CO 6241126A2
- Authority
- CO
- Colombia
- Prior art keywords
- group
- alkoxy
- formula
- alkyl
- integer
- Prior art date
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- -1 atoms halogen Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 abstract 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Esta invención está dirigida a nuevos inhibidores de proteína quinasa activada por mitógeno p38 que tienen la fórmula general (I)a procedimientos para su preparación, a composiciones farmacéuticas que los comprenden y a su uso en terapia.1.- Un compuesto de fórmula (I) para uso en el tratamiento del cuerpo humano o animal:en la que:G representa un átomo de nitrógeno o un grupo -CH-,R1 representa un átomo de halógeno, un grupo alquilo C1-4 opcionalmente sustituido con uno, dos o tres átomos de halógeno, o un grupo alcoxi C1-4, R2 representa un átomo de halógeno o un grupo seleccionado de hidroxi, alquilo C1-4, alcoxi C1-4, alquiltio C1-4, alcoxi C1-4 - alcoxi C1-4, morfolin-alcoxi C1-4, alcanosulfonamida C1-4 y (alcoxi C1-4 - alquiloC1-4)carbamoílo,R3 se selecciona de los grupos constituidos por un átomo de hidrogeno, un grupo hidroxi, grupos -NR4R5, -NH-(CH2)q-NR4R5, -S-(CH2)q-NR4R5, -O-(CH2)qNR4R5, NHS(O)2R4, -NHCOR4, -NHC(O)OR4, COOR4 y CONHR4,R4 y R5 se seleccionan independientemente del grupo constituido por un átomo de hidrógeno y un grupo alquilo C1-4, n es un número entero de 0 a 4, m es un número entero de 0 a 4, p tiene el valor de 0 ó 1, q es un número entero de 1-4, y sus sales farmacéuticamente aceptables, con la condición de que, cuando G es un grupo =CH-, R3 no puede ser un átomo de hidrógeno. 2.- Un compuesto según la reivindicación 1, en el que p, en la fórmula (I), tiene el valor de 1. 3.- Un compuesto según una cualquiera de las reivindicaciones 1 ó 2, en el que, en la fórmula (I), n es 1 ó 2 y cada R1 representa independientemente un átomo de halógeno o un grupo alquilo C1-4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200701132A ES2329639B1 (es) | 2007-04-26 | 2007-04-26 | Nuevos derivados de 4,8-difenilpoliazanaftaleno. |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6241126A2 true CO6241126A2 (es) | 2011-01-20 |
Family
ID=38671030
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO09120187A CO6241126A2 (es) | 2007-04-26 | 2009-10-26 | Nuevos derivados de 4,8-difenil-poliazanaftaleno |
Country Status (17)
Country | Link |
---|---|
US (1) | US8334294B2 (es) |
EP (1) | EP2146988B1 (es) |
JP (1) | JP2010524999A (es) |
KR (1) | KR20100015880A (es) |
CN (1) | CN101679417A (es) |
AU (1) | AU2008243339A1 (es) |
BR (1) | BRPI0809805A2 (es) |
CA (1) | CA2685247A1 (es) |
CO (1) | CO6241126A2 (es) |
EC (1) | ECSP099730A (es) |
ES (2) | ES2329639B1 (es) |
IL (1) | IL201444A0 (es) |
IN (1) | IN2009DN06586A (es) |
MX (1) | MX2009011576A (es) |
RU (1) | RU2009143551A (es) |
WO (1) | WO2008131922A1 (es) |
ZA (1) | ZA200907014B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2320955B1 (es) * | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
CN103969300B (zh) * | 2013-01-24 | 2016-08-17 | 湖北大学 | 一种识别cgg三核苷酸重复序列的双功能电活性探针、探针的制备及试剂盒 |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS57203068A (en) | 1981-06-08 | 1982-12-13 | Teikoku Hormone Mfg Co Ltd | Novel 1-phenylisoquinoline derivative |
WO1987004928A1 (en) | 1986-02-24 | 1987-08-27 | Mitsui Petrochemical Industries, Ltd. | Agents for treating neurophathy |
DE3932953A1 (de) | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
DE3935514A1 (de) | 1989-10-25 | 1991-05-02 | Boehringer Mannheim Gmbh | Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US5252536A (en) | 1991-12-31 | 1993-10-12 | American Cyanamid Company | Substituted indolinones useful as herbicidal agents |
JP3221234B2 (ja) | 1994-06-15 | 2001-10-22 | ミノルタ株式会社 | ズームレンズ鏡胴 |
EP0743066A3 (en) | 1995-05-16 | 1998-09-30 | Mitsui Pharmaceuticals, Inc. | Wound-healing agent |
JPH09104638A (ja) | 1995-10-06 | 1997-04-22 | Mitsui Pharmaceut Inc | 医薬・動物薬組成物 |
JPH1079183A (ja) | 1996-08-30 | 1998-03-24 | Sony Corp | 円盤状記録媒体のハブ接合装置 |
GB9713726D0 (en) | 1997-06-30 | 1997-09-03 | Ciba Geigy Ag | Organic compounds |
AU4429799A (en) * | 1998-06-12 | 1999-12-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of p38 |
US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
CO5170501A1 (es) | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
DK1171440T3 (da) * | 1999-04-21 | 2004-08-02 | Wyeth Corp | Substituerede 3-cyano-[1,7]-, [1,5]- og [1,8]-naphthyridininhibitorer af tyrosinkinaser |
EP1196167B1 (en) | 1999-07-02 | 2006-04-19 | Stuart A. Lipton | Use of p38 MAPK inhibitors in the treatment of ophthalmic conditions |
TR200201057T2 (tr) | 1999-10-21 | 2002-09-23 | F.Hoffmann-La Roche Ag | P38 protein kinazı inhibitörleri olarak heteroalkilamino ikameli bisiklik nitrojen heterosaykılları. |
AR028782A1 (es) | 2000-07-05 | 2003-05-21 | Taisho Pharmaceutical Co Ltd | Derivados heterociclicos tetrahidropiridino o piperidino |
ES2307667T3 (es) | 2000-12-05 | 2008-12-01 | Vertex Pharmaceuticals Incorporated | Inhibidires de quinasas terminales c-jun(jnk) y otras proteinas quinasas. |
AU2002246677B2 (en) * | 2000-12-20 | 2006-11-16 | Merck Sharp & Dohme Corp. | (Halo-Benzo Carbonyl)Heterocyclo Fused Phenyl p38 Kinase Inhibiting Agents |
AP2002002460A0 (en) | 2001-03-09 | 2002-06-30 | Pfizer Prod Inc | Novel benzimidazole anti-inflammatory compounds. |
CZ20032185A3 (en) | 2001-03-09 | 2004-06-16 | Pfizer Products Inc. | Triazolopyridines as anti-inflammatory agents |
GB0117506D0 (en) | 2001-07-18 | 2001-09-12 | Bayer Ag | Imidazopyridinones |
GB0124848D0 (en) | 2001-10-16 | 2001-12-05 | Celltech R&D Ltd | Chemical compounds |
AU2002352706A1 (en) | 2001-11-15 | 2003-06-10 | Maxia Pharmaceuticals, Inc. | N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases |
US6831102B2 (en) * | 2001-12-07 | 2004-12-14 | Bristol-Myers Squibb Company | Phenyl naphthol ligands for thyroid hormone receptor |
JP2005526831A (ja) | 2002-04-09 | 2005-09-08 | アステックス テクノロジー リミテッド | 医薬化合物 |
JP2005530788A (ja) | 2002-05-13 | 2005-10-13 | メルク エンド カムパニー インコーポレーテッド | フェニル置換イミダゾピリジン類およびフェニル置換ベンズイミダゾール類 |
AU2003238915B2 (en) | 2002-06-11 | 2008-02-21 | Merck & Co., Inc. | (halo-benzo carbonyl)heterobicyclic p38 kinase inhibiting agents |
CN1681823A (zh) | 2002-07-26 | 2005-10-12 | 武田药品工业株式会社 | 呋喃并异喹啉衍生物及其用途 |
GB0217757D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Novel compounds |
WO2004014900A1 (en) | 2002-08-09 | 2004-02-19 | Eli Lilly And Company | Benzimidazoles and benzothiazoles as inhibitors of map kinase |
PA8579601A1 (es) | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
BR0313961A (pt) | 2002-08-30 | 2005-07-19 | Pfizer Prod Inc | Processos e intermediários para preparar triazolo-piridinas |
CN1281590C (zh) | 2002-11-27 | 2006-10-25 | 南京凯衡科贸有限公司 | 具有抑制血管生成活性的六员氨基酰胺类衍生物 |
US7129252B2 (en) | 2003-06-16 | 2006-10-31 | Guoqing P Chen | Six membered amino-amide derivatives an angiogenisis inhibitors |
AU2004266719A1 (en) | 2003-08-22 | 2005-03-03 | Boehringer Ingelheim France S.A.S. | Methods of treating COPD and pulmonary hypertension |
US20060019971A1 (en) | 2003-09-30 | 2006-01-26 | Higgins Linda S | Treatment of cardiovascular disease with inhibitors of p38 kinase |
BRPI0417543A (pt) * | 2003-12-12 | 2007-03-27 | Wyeth Corp | quinolinas úteis no tratamento de doença cardiovascular |
US20050165032A1 (en) | 2004-01-23 | 2005-07-28 | Norman Mark H. | Vanilloid receptor ligands and their use in treatments |
GB0402140D0 (en) | 2004-01-30 | 2004-03-03 | Smithkline Beecham Corp | Novel compounds |
SI1761528T1 (sl) | 2004-06-11 | 2008-06-30 | Japan Tobacco Inc | 5-amino-2,4,7-triokso-3,4,7,8-tetrahidro-2H-pirido(2,3-D)pirimidinski derivati in sorodne spojine za zdravljenje raka |
JP5169220B2 (ja) | 2005-11-30 | 2013-03-27 | アステラス製薬株式会社 | 2−アミノベンズアミド誘導体 |
EP1991540A1 (en) | 2006-02-21 | 2008-11-19 | Amgen Inc. | Cinnoline derivatives as phosphodiesterase 10 inhibitors |
US7495007B2 (en) | 2006-03-13 | 2009-02-24 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
ES2301380B1 (es) * | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | Nuevos derivados de 1,7-naftiridina. |
ES2377821T3 (es) | 2006-10-11 | 2012-04-02 | Amgen Inc. | Compuestos de imidazo- y triazolo-piridina y métodos de uso de los mismos. |
ES2320955B1 (es) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida. |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
-
2007
- 2007-04-26 ES ES200701132A patent/ES2329639B1/es not_active Withdrawn - After Issue
-
2008
- 2008-04-25 KR KR1020097022264A patent/KR20100015880A/ko not_active Application Discontinuation
- 2008-04-25 MX MX2009011576A patent/MX2009011576A/es not_active Application Discontinuation
- 2008-04-25 EP EP08749136A patent/EP2146988B1/en active Active
- 2008-04-25 BR BRPI0809805 patent/BRPI0809805A2/pt not_active Application Discontinuation
- 2008-04-25 IN IN6586DEN2009 patent/IN2009DN06586A/en unknown
- 2008-04-25 CN CN200880013548A patent/CN101679417A/zh active Pending
- 2008-04-25 ES ES08749136T patent/ES2392205T3/es active Active
- 2008-04-25 RU RU2009143551/04A patent/RU2009143551A/ru not_active Application Discontinuation
- 2008-04-25 WO PCT/EP2008/003357 patent/WO2008131922A1/en active Application Filing
- 2008-04-25 JP JP2010504556A patent/JP2010524999A/ja active Pending
- 2008-04-25 US US12/597,187 patent/US8334294B2/en not_active Expired - Fee Related
- 2008-04-25 CA CA002685247A patent/CA2685247A1/en not_active Abandoned
- 2008-04-25 AU AU2008243339A patent/AU2008243339A1/en not_active Abandoned
-
2009
- 2009-10-08 ZA ZA200907014A patent/ZA200907014B/xx unknown
- 2009-10-11 IL IL201444A patent/IL201444A0/en unknown
- 2009-10-26 CO CO09120187A patent/CO6241126A2/es not_active Application Discontinuation
- 2009-11-12 EC EC2009009730A patent/ECSP099730A/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL201444A0 (en) | 2010-06-16 |
EP2146988B1 (en) | 2012-08-15 |
CA2685247A1 (en) | 2008-11-06 |
IN2009DN06586A (es) | 2015-07-24 |
EP2146988A1 (en) | 2010-01-27 |
CN101679417A (zh) | 2010-03-24 |
JP2010524999A (ja) | 2010-07-22 |
ES2329639B1 (es) | 2010-09-23 |
BRPI0809805A2 (pt) | 2015-03-24 |
KR20100015880A (ko) | 2010-02-12 |
ES2329639A1 (es) | 2009-11-27 |
WO2008131922A1 (en) | 2008-11-06 |
ECSP099730A (es) | 2009-12-28 |
US20100130517A1 (en) | 2010-05-27 |
MX2009011576A (es) | 2009-11-09 |
US8334294B2 (en) | 2012-12-18 |
AU2008243339A1 (en) | 2008-11-06 |
RU2009143551A (ru) | 2011-06-10 |
ES2392205T3 (es) | 2012-12-05 |
ZA200907014B (en) | 2010-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
UY30942A1 (es) | Nuevos derivados de 3-([1,2,4,]triazolo[4,3-a]piridin-7-il)benzamida | |
AR071120A1 (es) | Derivados de diosmetina, su procedimiento de preparacion, las composiciones farmaceuticas que los contienen y su uso en el tratamiento de las enfermedades venosas cronicas. | |
ECSP105253A (es) | Derivados de 5-feniltiazol y uso como inhibidores de pi3 cinasa | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
CO2022002842A2 (es) | Degradadores bifuncionales de brd9 y sus métodos de uso | |
CO2017004517A2 (es) | Inhibidores de las tirosina cinasas de bruton derivados de la 2, 3, 4, 9-tetrahidro-ih-carbazol-8- carboxamida y 9h-carbazol-l-carboxamida, composiciones que los comprenden y metodos de elaboration | |
GT200500325A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
UY31254A1 (es) | Derivados sutituidos de n4-(5-metil-1h-pirazol-3-il)- 1,3,5-triazina-2,4-diamina, sus enantiómeros, sales farmacéuticamente aceptables de los mismos, composiciones, procesos de preparación y aplicaciones | |
UY28671A1 (es) | Pirido(2.3-d)pirimidina-2,4-diaminas como inhibidores de pde 2 | |
AR092289A1 (es) | Derivados de aminoquinazolina y sus sales y metodos de uso | |
NI201000119A (es) | Compuestos de 3h-[1,2,3]triazolo[4,5-d] pirimidina, su uso como inhibidores de cinasa mtor y cinasa pi3, y sus síntesis. | |
UY29087A1 (es) | Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico | |
AR056511A1 (es) | Derivados de 2-aminopirimidinas, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor de histamina h4 | |
NI201100062A (es) | Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38. | |
AR054320A1 (es) | Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas | |
UY33500A (es) | Derivados de acil sulfonamida y sus sales farmacéuticamente aceptables para uso en medicina | |
BRPI0408068A (pt) | derivados de 5-feniltiazol e seus usos como inibidores de pi3 cinase | |
GT200500020A (es) | Derivados de 1h-tieno[2,3-c]pirazol utiles como inhibidores de quinasa. | |
CO6241126A2 (es) | Nuevos derivados de 4,8-difenil-poliazanaftaleno | |
CO5611124A2 (es) | Derivados de benzofurano substituidos utiles en el tratamiento de desordenes hiper-proliferativos | |
AR114082A1 (es) | INHIBIDORES DE LA PI4KIIIb | |
CO2018012020A2 (es) | Derivados de piridinilo, composiciones farmacéuticas y sus usos como inhibidores aoc3 | |
AR069781A1 (es) | Compuestos de n-(2,3-dihidro-inden-2-il) propanosulfonamida, composicion farmaceutica que los comprenden y su uso para el tratamiento de la ezquizofrenia. | |
PA8720601A1 (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevenciòn de trastornos psicoticos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Application withdrawn |